RT Journal Article
SR Electronic
T1 Integrative genetic analysis of the amyotrophic lateral sclerosis spinal cord implicates glial activation and suggests new risk genes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.31.21262682
DO 10.1101/2021.08.31.21262682
A1 Humphrey, Jack
A1 Venkatesh, Sanan
A1 Hasan, Rahat
A1 Herb, Jake T.
A1 de Paiva Lopes, Katia
A1 Küçükali, Fahri
A1 Byrska-Bishop, Marta
A1 Evani, Uday S.
A1 Narzisi, Giuseppe
A1 Fagegaltier, Delphine
A1 ,
A1 Sleegers, Kristel
A1 Phatnani, Hemali
A1 Knowles, David A.
A1 Fratta, Pietro
A1 Raj, Towfique
YR 2021
UL http://medrxiv.org/content/early/2021/09/02/2021.08.31.21262682.abstract
AB Amyotrophic lateral sclerosis (ALS) is a progressively fatal neurodegenerative disease affecting motor neurons in the brain and spinal cord. We used 380 post-mortem tissue RNA-seq transcriptomes from 154 ALS cases and 49 control individuals from cervical, thoracic, and lumbar spinal cord segments to investigate the gene expression response to ALS. We observed an increase in microglia and astrocyte expression, accompanied by a decrease in oligodendrocytes. By creating a gene co-expression network in the ALS samples, we identify several activated microglia modules that negatively correlate with retrospective disease duration.We map molecular quantitative trait loci and find several potential ALS risk loci that may act through gene expression or splicing in the spinal cord and assign putative cell-types for FNBP1, ACSL5, SH3RF1 and NFASC. Finally, we outline how repeat expansions that alter splicing of C9orf72 are tagged by common variants, and use this to suggest ATXN3 as a putative risk gene.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJH, KPL and TR are funded by grants from the US National Institutes of Health (NIH NIA R56-AG055824 and NIA U01-AG068880). JTH is funded by an NIH Medical Scientist Training Program grant (T3GM007280). FK is supported by a BOF DOCPRO fellowship of the University of Antwerp Research Fund. PF is funded by the UK MRCl (MR/M008606/1 and MR/S006508/1), the UK Motor Neurone Disease Association, Rosetrees Trust and the UCLH NIHR Biomedical Research Centre. This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health under award number S10OD018522 and S10OD026880. All NYGC ALS Consortium activities are supported by the ALS Association (ALSA, 19-SI-459) and the Tow Foundation. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The NYGC ALS Consortium samples presented in this work were acquired through various IRB protocols from member sites and the Target ALS postmortem tissue core and transferred to the NYGC in accordance with all applicable foreign, domestic, federal, state, and local laws and regulations for processing, sequencing, and analysis. ​​The Biomedical Research Alliance of New York (BRANY) Institutional Review Board serves as the central ethics oversight body for NYGC ALS Consortium. Ethical approval was given and is effective through 08/22/2022.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw RNA-seq data can be accessed via the NCBI's GEO database (GEO GSE137810, GSE124439, GSE116622, and GSE153960). Whole genome sequencing data will be uploaded to dbGaP upon publication. Full summary statistics for expression and splicing QTLs have been deposited on Zenodo (10.5281/zenodo.5248758). All TWAS weight files have been deposited on Zenodo (10.5281/zenodo.5256613). All RNA-seq and whole genome sequencing data generated by the NYGC ALS Consortium are made immediately available to all members of the Consortium and with other consortia with whom we have a reciprocal sharing arrangement. To request immediate access to new and ongoing data generated by the NYGC ALS Consortium and for samples provided through the Target ALS Postmortem Core, complete a genetic data request form at CGND_help@nygenome.org. https://zenodo.org/record/5248758 https://github.com/jackhump/ALS_SpinalCord_QTLs